Laura Clague Travere Therapeutics, Inc. (TVTX) insider trading activity

Laura Clague is Chief Financial Officer of Travere Therapeutics, Inc.. Currently has a direct ownership of 35,655 shares of TVTX, which is worth approximately $650,703. The most recent transaction as insider was on May 11, 2022, when has been sold 1,375 shares (Common Stock) at a price of $21.51 per share, resulting in proceeds of $29,576. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 35.7K

0% 3M change

0% 12M change

Total Value Held $650,703

Laura Clague Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 11 2022	SELL Open market or private sale	$29,576 $21.51 p/Share	1,375 Reduced 3.71%	35,655 Common Stock
May 10 2022	SELL Open market or private sale	$17,746 $21.51 p/Share	825 Reduced 2.18%	37,030 Common Stock
Jan 31 2022	SELL Open market or private sale	$33,921 $27.4 p/Share	1,238 Reduced 3.17%	37,855 Common Stock
Jan 31 2022	BUY Grant, award, or other acquisition	-	9,840 Added 20.11%	39,093 Common Stock
Jan 24 2022	SELL Open market or private sale	$51,534 $24.98 p/Share	2,063 Reduced 6.59%	29,253 Common Stock
Jan 11 2022	SELL Open market or private sale	$205,500 $27.4 p/Share	7,500 Reduced 19.32%	31,316 Common Stock
Jan 10 2022	BUY Grant, award, or other acquisition	-	7,500 Added 16.19%	38,816 Common Stock
Aug 17 2021	SELL Open market or private sale	$24,088 $17.12 p/Share	1,407 Reduced 4.3%	31,316 Common Stock
Aug 13 2021	BUY Grant, award, or other acquisition	-	4,500 Added 12.09%	32,723 Common Stock
May 12 2021	SELL Open market or private sale	$38,920 $19.46 p/Share	2,000 Reduced 6.62%	28,223 Common Stock
May 11 2021	SELL Open market or private sale	$38,280 $19.14 p/Share	2,000 Reduced 6.21%	30,223 Common Stock
Feb 08 2021	SELL Open market or private sale	$71,055 $31.58 p/Share	2,250 Reduced 6.53%	32,223 Common Stock
Feb 05 2021	SELL Open market or private sale	$70,672 $31.41 p/Share	2,250 Reduced 6.13%	34,473 Common Stock
Feb 03 2021	SELL Open market or private sale	$104,799 $28.91 p/Share	3,625 Reduced 10.11%	32,223 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	4,500 Added 10.92%	36,723 Common Stock
Feb 02 2021	SELL Open market or private sale	$111,469 $30.75 p/Share	3,625 Reduced 9.18%	35,848 Common Stock
Jan 31 2021	BUY Grant, award, or other acquisition	-	5,000 Added 11.24%	39,473 Common Stock
Jan 21 2021	BUY Grant, award, or other acquisition	-	15,000 Added 30.32%	34,473 Common Stock
Nov 25 2020	SELL Open market or private sale	$85,200 $22.72 p/Share	3,750 Reduced 16.15%	19,473 Common Stock
Nov 24 2020	SELL Open market or private sale	$89,475 $23.86 p/Share	3,750 Reduced 13.9%	23,223 Common Stock
Nov 23 2020	BUY Grant, award, or other acquisition	-	7,500 Added 21.76%	26,973 Common Stock
Nov 16 2020	SELL Open market or private sale	$179,850 $23.98 p/Share	7,500 Reduced 27.81%	19,473 Common Stock
Nov 13 2020	SELL Open market or private sale	$177,075 $23.61 p/Share	7,500 Reduced 21.76%	26,973 Common Stock
Nov 11 2020	BUY Grant, award, or other acquisition	-	15,000 Added 30.32%	34,473 Common Stock

Also insider at

LAB

STANDARD BIOTOOLS INC. Healthcare

Director

GNSS

Genasys Inc. Technology

Director

Laura Clague

Chief Financial Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Value

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX

Account